Skip to main content

Advertisement

Table 4 Overall survival and progression-free survival from the start of second-line targeted therapy according to MSKCC and IMDC risk groups (patients with evaluable MSKCC score, n = 1029; patients with evaluable IMDC score, n = 540)

From: Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry

Prognostic score n Median OS (months) (95% CI) Median PFS (months) (95% CI)
IMDC good 178 20.2 (13.6–26.8) 6.9 (5.0–8.8)
IMDC intermediate 314 17.0 (13.1–20.9) 5.8 (5.1–6.5)
IMDC poor 48 11.5 (5.3–17.7) 3.7 (2.8–4.6)
MSKCC good 378 19.2 (16.3–22.0) 7.3 (6.1–8.6)
MSKCC intermediate 596 15.7 (13.5–17.9) 6.0 (5.4–6.5)
MSKCC poor 55 5.5 (3.1–7.8) 3.7 (3.0–4.3)
  1. IMDC International Metastatic Renal Cell Carcinoma Database Consortium, MSKCC Memorial Sloan Kettering Cancer Center, OS overall survival, PFS progression-free survival